Atlas of Cardiac Positron Emission Tomography

  • Johannes Czernin
  • Heinrich R. Schelbert
Part of the Atlases of Clinical Nuclear Medicine book series (ATLASES)


Positron emission tomography (PET) surpasses the capabilities of conventional radionuclide imaging techniques including single photon emission computed tomography (SPECT) for several reasons: a) a virtually unlimited number of positron emitting tracers of biological substrates b) the ability to derive regional activity concentrations directly from the cross-sectional PET images as a result of appropriately corrected photon attenuation c) the visualization of considerable anatomical detail and of subtle differences in tracer concentrations due to the high spatial and contrast resolution and d) the ability to measure rapidly changing tracer tissue concentrations because of the high temporal resolution. Taken together, these features permit the in vivo application of tracer kinetic principles. Consequently, regional functional processes can be quantified noninvasively so that PET has become a noninvasive biochemical assay technique for probing regional functional processes in human myocardium. While a powerful research tool, PET also contributes substantially to the diagnosis of cardiac disease and for determining its severity. Foremost among these clinical applications are a) the detection of coronary artery disease and b) the assessment of myocardial viability. This chapter describes the technical aspects of currently employed PET approaches in clinical cardiology, including manipulation, interpretation, and quantitative analysis of images of myocardial blood flow and of glucose metabolism, and the integration of PET findings into the overall diagnostic process.


Positron Emission Tomography Myocardial Blood Flow Pharmacologic Stress Chronic Coronary Artery Disease Cardiac Positron Emission Tomography 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Tillisch J, Brunken R, Marshall R, et al. Reversibility of cardiac wall motion abnormalities predicted by positron tomography. N Engl J Med. 1986; 314: 884–888.PubMedCrossRefGoogle Scholar
  2. 2.
    Tamaki N, Yonekura Y, Yamashita K, et al. Positron emission tomography using fluorine-18 deoxyglucose in evaluation of coronary artery bypass grafting. Am J Cardiol. 1989; 64: 860–865.PubMedCrossRefGoogle Scholar
  3. 3.
    Tamaki N, Ohtani H, Yamashita K, et al. Metabolic activity in the areas of new fill-in after thallium-201 reinjection: comparison with positron emission tomography using fluorine-18-deoxyglucose. JNucl Med. 1991; 32: 673–678.Google Scholar
  4. 4.
    Marwick T, Maclntyre W, Lafont A, Nemec J, Salcedo E. Metabolic responses of hibernating and infarcted myocardium to revascularization: a follow-up study of regional perfusion, function, and metabolism. Circulation 1992; 85 (4): 1347–1353.PubMedGoogle Scholar
  5. 5.
    Vaghaiwalla Mody F, Brunken R, Warner-Stevenson L, Nienaber C, Phelps M, Schelbert H. Differentiating cardiomyopathy of coronary artery disease from non-ischemic dilated cardiomyopathy utilizing positron tomography. J Am Coll Cardiol. 1991; 17: 373–383.CrossRefGoogle Scholar
  6. 6.
    Schelbert H R, Wisenberg G, Phelps M E, et al. Noninvasive assessment of coronary stenoses by myocardial imaging during pharmacologic coronary vasodilation. VI. Detection of coronary artery disease in man with intravenous N-13 ammonia and positron computed tomography. Am J Cardiol. 1982; 49: 1197–1207.PubMedCrossRefGoogle Scholar
  7. 7.
    Demer L L, Gould K L, Goldstein R A, et al. Assessment of coronary artery disease severity by positron emission tomography. Comparison with quantitative arteriography in 193 patients. Circulation. 1989; 79: 825–835.PubMedCrossRefGoogle Scholar
  8. 8.
    Gould K L, Goldstein R A, Mullani N A, et al. Noninvasive assessment of coronary stenoses by myocardial perfusion imaging during pharmacologic coronary vasodilation. VIII. Clinical feasibility of positron cardiac imaging without a cyclotron using generator-produced rubidium-82. J Am Coll Cardiol. 1986; 7: 775–789.PubMedCrossRefGoogle Scholar
  9. 9.
    Nienaber C, Brunken R, Sherman C, et al. Metabolic and functional recovery of ischemic human myocardium after coronary angioplasty. J Am Coll Cardiol. 1991; 18: 966–78.PubMedCrossRefGoogle Scholar
  10. 10.
    Tamaki N, Yonekura Y, Senda M, et al. Value and limitation of stress thallium-201 single photon emission computed tomography: comparison with nitrogen-13 ammonia positron tomography. JNucl Med. 1988; 29: 1181 1188.Google Scholar
  11. 11.
    Porenta G, Kuhle W, Czernin J, et al. Semiquantitative assessment of myocardial viability and perfusion utilizing polar map displays of cardiac PET images. JNucl Med. 1992; 33: 1623–1631.Google Scholar
  12. 12.
    Kuhle W, Porenta G, Huang S-C, Phelps M, Schelbert H. Issues in the quantitation of reoriented cardiac PET images. J Nucl Med. 1992; 33: 1235 1242.Google Scholar
  13. 13.
    Budinger T F, Yano Y, Derenzo S E, et al. Rb-82 myocardial positron emission tomography. J Nucl Med. 1979; 20: P603.Google Scholar
  14. 14.
    Budinger T F, Yano Y, Moyer B, Twitchell J, Huesman R H. Myocardial extraction of Rb-82 vs. flow determined by positron emission tomography. J Nucl Med. 1983; 68 (Suppl III): III - 81.Google Scholar
  15. 15.
    Love W D, Burch G E. Influence of the rate of coronary plasma flow on the extraction of Rb86 from coronary blood. Circ Res. 1959; VII: 24–30.Google Scholar
  16. 16.
    Schelbert H R, Phelps M E, Hoffman E J, Huang S C, Selin C E, Kuhl D E. Regional myocardial perfusion assessed with N-13 labeled ammonia and positron emission computerized axial tomography. Am J Cardiol. 1979; 43: 209–218.PubMedCrossRefGoogle Scholar
  17. 17.
    Schelbert H R, Phelps M E, Huang S C, et al. N-13 ammonia as an indicator of myocardial blood flow. Circulation. 1981; 63: 1259–1272.PubMedCrossRefGoogle Scholar
  18. 18.
    Bergmann S R, Fox K A A, Rand A L, et al. Quantification of regional myocardial blood flow in vivo with H215O. Circulation. 1984; 70: 724–733.PubMedCrossRefGoogle Scholar
  19. 19.
    Sokoloff L, Reivich M, Kennedy C, et al. The [14C]-deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure and normal values in the conscious and anesthetized albino rat. J Neurochem. 1977; 28: 897–916.PubMedCrossRefGoogle Scholar
  20. 20.
    Phelps M E, Hoffman E J, Selin C E, et al. Investigation of [18F]2-fluoro-2deoxyglucose for the measure of myocardial glucose metabolism. J Nucl Med. 1978; 19: 1311–1319.PubMedGoogle Scholar
  21. 21.
    Ratib O, Phelps M E, Huang S C, Henze E, Selin C E, Schelbert H R. Positron tomography with deoxyglucose for estimating local myocardial glucose metabolism. JNucl Med. 1982; 23: 577–586.Google Scholar
  22. 22.
    Choi Y, Brunken R, Hawkins R, et al. Determinants of myocardial glucose utilization assessed with dynamic FDG PET. Circulation. 1991; 84: II - 425.Google Scholar
  23. 23.
    Kalff V, Schwaiger M, Nguyen N, McClanahan T B, Gallagher K P. The relationship between myocardial blood flow and glucose uptake in ischemic canine myocardium determined with fluorine-l8-deoxyglucose. J Nucl Med. 1992; 33 (7): 1346–1353.PubMedGoogle Scholar
  24. 24.
    Gropler R, Siegel B, Lee K, et al. Nonuniformity in myocardial accumulation of fluorine-18-fluorodeoxyglucose in normal fasted humans J Nuc Med. 1990; 31 (11): 1749–1756.Google Scholar
  25. 25.
    Berry J, Baker J, Pieper K, Hanson M, Hoffman J, Coleman R. The effect of metabolic milieu on cardiac PET imaging using fluorine-18-deoxyglucose and nitrogen-13- ammonia in normal volunteers. J Nucl Med. 1991; 32: 1518 1525.Google Scholar
  26. 26.
    Bonow R, Dilsizian V, Cuocolo A, Bacharach S. Identification of viable myocardium in patients with chronic coronary artery disease and left ventricular dysfunction: comparison of thallium scintigraphy with reinjection and PET imaging with F-18-fluorodeoxyglucose. Circulation. 1991; 83 (1): 26–37.PubMedGoogle Scholar
  27. 27.
    Go R, Marwick T, Maclntyre W, et al. A prospective comparison of rubidium-82 PET and thallium-201 SPECT myocardial perfusion imaging utilizing a single dipyridamole stress in the diagnosis of coronary artery disease. J Nucl Med. 1990; 31: 1899–1905.PubMedGoogle Scholar
  28. 28.
    Stewart R, Schwaiger M, Molina E, et al. Comparison of rubidium-82 positron emission tomography and thallium-201 SPECT imaging for detection of coronary artery disease. Am J Cardiol. 1991; 67: 1303–1310.PubMedCrossRefGoogle Scholar
  29. 29.
    Eitzman D, Al-Aouar Z, Kanter H, et al. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. JAm Coll Cardiol. 1992; 20 (3): 559–565.CrossRefGoogle Scholar
  30. 30.
    Maddahi J, DiCarli M, Davidson M, et al. Prognostic significance of PET assesment of myocardial viability in patients with left ventricular dysfunction. JAm Coll Cardiol. 1992; 19: 142A.Google Scholar
  31. 31.
    Marwick T, Nemec J, Lafont A, Salcedo E, MacIntyre W. Prediction by postexercise fluoro-18 deoxyglucose positron emission tomography of improvement in exercise capacity after revascularization. Am J Cardiol. 1992; 69: 854–859.PubMedCrossRefGoogle Scholar
  32. 32.
    Ragosta M, Beller G, Watson D, Kaul S, Gimple L. Can resting thallium-201 imaging predict improvement in function after revascularization in patients with severely reduced left ventricle function? Circulation. 1991; 84: 1189.Google Scholar
  33. 33.
    Mori T, Minamiji K, Kurogane H, Ogawa K, Yoshida Y. Rest-injected thallium-201 imaging for assessing viability of severe asynergic regions. J Nucl Med. 1991; 32: 1718–1724.PubMedGoogle Scholar
  34. 34.
    Brunken R, Mody F, Hawkins R, Nienaber C, Phelps M, Schelbert H. Metabolic imaging with Positron Emission Tomography detects viable tissue in myocardial segments with persistent defects on twenty-four hour torno-graphic thallium-201 scintigraphy. Circulation. 1992; 86: 1357–1369.PubMedGoogle Scholar
  35. 35.
    Iida H, Rhodes C, de Silva R, et al. Myocardial tissue fraction—correction for partial volume effects and measure of tissue viability. JNucl Med. 1991; 32: 2169–2175.Google Scholar
  36. 36.
    DeSilva R, Yamamoto Y, Rhodes C, et al. Detection of hibernating myocardium using H2 150 and positron emission tomography (PET). J Am Coll Cardiol. 1992; 19: 141A.Google Scholar
  37. 37.
    Yamamoto Y, de Silva R, Rhodes C, et al. A new strategy for the assessment of viable myocardium and regional myocardial blood flow using 150-water and dynamic positron emission tomography. Circulation. 1992;86(1):167178.Google Scholar
  38. 38.
    Gropler R, Siegel B, Sampathkumaran K, et al. Dependence of recovery of contractile function on maintenance of oxidative metabolism after myocardial infarction. JAm Coll Cardiol. 1992; 19: 989–997.CrossRefGoogle Scholar
  39. 39.
    Gropler R, Geltman E, Sampathkumaran K, et al. Functional recovery after coronary revascularization for chronic coronary artery disease is dependent on maintenance of oxidative metabolism. J Am Coll Cardiol. 1992; 20 (3): 569–77.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York, Inc. 1994

Authors and Affiliations

  • Johannes Czernin
  • Heinrich R. Schelbert

There are no affiliations available

Personalised recommendations